SCHEMBL3014869

SCHEMBL3014869

Cc1ccc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.40
KIT P10721 1/20 0.36
CHRM4 P08173 1/20 0.36
EPHX2 P34913 2/20 0.35
GBA1 P04062 1/20 0.35
FFAR4 Q5NUL3 1/20 0.34
EPHX1 P07099 1/20 0.34
HTR2A P28223 1/20 0.34
RORC P51449 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
DNM1L O00429 1/20 0.34
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
AVPR1B P47901 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008424 0.90 LIPE (0.37) LIPEKITCHRM4EPHX2GBA1
SCHEMBL3011496 0.90 GBA1 (0.42) GBA1DNM1LALDH1A1CYP1A2POLB
SCHEMBL3018098 0.88 FFAR4 (0.39) LIPEKITCHRM4EPHX2GBA1
SCHEMBL3016941 0.88 LIPE (0.44) LIPECHRM4EPHX2GBA1EPHX1
SCHEMBL3004883 0.88 HTR2A (0.40) EPHX2GBA1HTR2ADNM1LALDH1A1
SCHEMBL3011689 0.87 LIPE (0.37) LIPEKITCHRM4EPHX2FFAR4
SCHEMBL3016319 0.87 LIPE (0.40) LIPEKITCHRM4EPHX2GBA1
SCHEMBL3013654 0.87 DRD2 (0.39) EPHX2GBA1HTR2ADNM1LALDH1A1
SCHEMBL3015376 0.87 LIPE (0.36) LIPEKITCHRM4GBA1HTR2A
SCHEMBL3019380 0.87 LIPE (0.38) LIPEKITCHRM4EPHX2GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LIPE 2030/4885KIT 4404/4885CHRM4 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.